The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vasenina E.E.

Russian Medical Academy of Continuous Professional Education

Verugina N.I.

Russian Medical Academy of Continuous Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Capabilities of combined therapy of Alzheimer’s disease

Authors:

Vasenina E.E., Verugina N.I., Levin O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11‑2): 45‑50

DOI: 10.17116/jnevro202212211245

Read: 5219 times

Download PDF (RU)
Contact the author
Table of contents

CAPABILITIES OF COMBINED THERAPY OF ALZHEIMER’S DISEASE
CAPABILITIES OF COMBINED THERAPY OF ALZHEIMER’S DISEASE

To cite this article:

Vasenina EE, Verugina NI, Levin OS. Capabilities of combined therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11‑2):45‑50. (In Russ.)
https://doi.org/10.17116/jnevro202212211245

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
The rela­tionship between neuropsychological indi­cators and neuroimaging changes acco­rding to MRI morphometry in patients with Alzheimer’s disease and glaucoma. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):142-152
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Effi­cacy of combined therapy of prurigo adultorum with application of temgicoluril anxiolytic. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):210-216
Abstract:

Alzheimer’s disease is one of the most common neurodegenerative diseases worldwide and carries a huge social burden. Unfortunately, no disease-modifying drug has been approved so far. Currently approved medications are symptomatic and include two classes: cholinesterase inhibitors, such as donepezil, and NMDA receptor antagonist memantine. Most studies have shown that a combination of both classes is better than monotherapy. The review discusses the pharmacological properties, efficacy and safety data of memantine and donepezil.

Keywords:

Alzheimer’s disease
memantine
donepezil
therapy
mioreol

Authors:

Vasenina E.E.

Russian Medical Academy of Continuous Professional Education

Verugina N.I.

Russian Medical Academy of Continuous Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Received:

12.09.2022

Accepted:

15.09.2022

Close metadata

References:

  1. Levin OS. Diagnostika i lechenie dementsii v klinicheskoj praktike. M.: MEDpress-inform; 2010. (In Russ.).
  2. Vasenina EE, Trusova NA, Gankina OA, Levin OS. Combination therapy of Alzheimer’s disease. Modern Therapy in Psychiatry and Neurology. 2013;2:10-15. (In Russ.).
  3. Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14):1326-1334. https://doi.org/10.1056/NEJMsa1204629
  4. Mebane-Sims I. Alzheimer’s Association, 2018. Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2018;14(3):367-429. 
  5. Levin OS, Vasenina EE. Twenty-five years of the amyloid hypothesis of Alzheimer’s disease: advances, failures and new perspectives. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6-2):3-9. (In Russ.). https://doi.org/10.17116/jnevro2016116623-9
  6. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. 2013;24(3):358-369.  https://doi.org/10.1007/s12640-013-9398-z
  7. Danysz W, Parsons CG. Alzheimer’s disease, beta-amyloid, glutamate, NMDA receptors and memantine — searching for the connections. Br J Pharmacol. 2012;167(2):324-352.  https://doi.org/10.1111/j.1476-5381.2012.02057.x
  8. Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Design Develop Ther. 2016;10:3267-3279. https://doi.org/10.2147/DDDT.S86463
  9. Atri A. Current and future treatments in Alzheimer’s disease. Semin Neurol. 2019;39(2):227-240.  https://doi.org/10.1055/s-0039-1678581
  10. Li Y, Sun H, Chen Z, et al. Implications of GABAergic neurotransmission in Alzheimer’s disease. Front Aging Neurosci. 2016;8:31-43.  https://doi.org/10.3389/fnagi.2016.00031
  11. Shi M. Chu F, Zhu F, Zhu J. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience. 2022;14:1-11.  https://doi.org/10.3389/fnagi.2022.870517
  12. Luo JJ, Wallace W, Kusiak JW. A tough trek in the development of an anti-amyloid therapy for Alzheimer’s disease: Do we see hope in the distance? J Neurol Sci. 2022;438(6);134-139.  https://doi.org/10.1016/j.jns.2022.120294
  13. Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014;13(6):759-774. 
  14. Khoury R, Patel K, Gold J, et al. Recent progress in the pharmacotherapy of Alzheimer’s disease. Drugs Aging. 2017;34(11):811-820.  https://doi.org/10.1007/s40266-017-0499-x
  15. Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821-827.  https://doi.org/10.1124/jpet.102.041616
  16. Blanco-Silvente L, Castells X, Saez M, et al. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease: A meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol. 2017;20(7):519-528.  https://doi.org/10.1093/ijnp/pyx012
  17. O’Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147-168.  https://doi.org/10.1177/0269881116680924
  18. Chen R, Chan P-T, Chu H, et al. Treatment effects between mono-therapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis. PLoS One. 2017;12(8):1-14.  https://doi.org/10.1371/journal.pone.0183586
  19. Kishi T, Matsunaga S, Oya K, et al. Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis. J Alzheimers Dis. 2017; 60(2):401-425.  https://doi.org/10.3233/JAD-170424
  20. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.  https://doi.org/10.1001/jama.291.3.317
  21. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-221.  https://doi.org/10.1097/WAD.0b013e31816653bc
  22. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600-607.  https://doi.org/10.1136/jnnp.2008.158964
  23. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366:893-903.  https://doi.org/10.1056/NEJMoa1106668
  24. Tkacheva ON, Runikhina NK, Mkhitaryan EA, Koberskaya NN, Manevich TM. Comparatative analysis of the effectiveness of Donepezil monotherapy and combination therapy with Donepezil and Akatinol Memantine in patients with Alzheimer’s disease at the stage of mild dementia. Russian Neurological Journal. 2019;24(5):54-60. (In Russ.). https://doi.org/10.30629/2658-7947-2019-24-5-54-60
  25. Vasenina EE. Efficacy of long-term therapy with cholinesterase inhibitors in Lewy body dementia: Diss. ... Cand. of Med. Sciences. M., 2012:113. 
  26. Owen RT. Memantine and donepezil: A fixed drug combination for the treatment of moderate to severe Alzheimer’s dementia. Drugs Today (Barc). 2016;52(4):239-248. 
  27. Ugurlu T, Ozaydin T. An overview on fixed dose combinations. Asian J Pharm Technol Innovation. 2014;2(9):75-81. 
  28. Smolyarchuk EA, Leykin ZN. Comparatative clinical study of the pharmacokinetics and bioequivalence of the combined drug Mioreol and combined use of mono-drugs containing Donepezil and Memantine. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(3):85-91. (In Russ.). https://doi.org/10.17116/jnevro202212203185
  29. Smith D, Lovell J, Weller C, et al. systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One. 2017;12(2):1-19.  https://doi.org/10.1371/journal.pone.0170651
  30. Kim DH, Brown RT, Ding EL, et al. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019-1031. https://doi.org/10.1111/j.1532-5415.2011.03450.x
  31. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211-225. 
  32. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6:1-245.  https://doi.org/10.1002/14651858.CD001190.pub3
  33. Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol.2004;58(1):1-8.  https://doi.org/10.1111/j.1365-2125.2004.01848.x
  34. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867-873.  https://doi.org/10.1001/archinternmed.2009.43
  35. Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Safety. 2008;31(7):577-585.  https://doi.org/10.2165/00002018-200831070-00003
  36. Mayer M, Pulte I. How safe is combination memantine/donepezil treatment in people with Alzheimer’s disease? Safety evaluations based on 23 clinical studies. Alzheimers Dement. 2013;9(4):282.  https://doi.org/10.1016/j.jalz.2013.05.565
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.